Michael Heffernan

Michael Heffernan, chairman and chief executive officer, Avenge Bio, discussed AVB-001's lower systemic toxicity profile seen in preclinical studies.

Michael Heffernan, chairman and chief executive officer, Avenge Bio, discussed the IND clearance of AVB-001 and the soon-to-initiate phase 1 trial.